Education
About Us
Working with TipRanks
Follow Us
Savara (SVRA)
NASDAQ:SVRA
SVRA Stock Chart & Stats
$5.27
$0.04(1.15%)
At close: 4:00 PM EST
$5.27
$0.04(1.15%)
Day’s Range― - ―
52-Week Range$1.89 - $7.01
Previous CloseN/A
Volume189.20K
Average Volume (3M)1.44M
Market Cap
$1.07B
Enterprise Value$1.09B
Total Cash (Recent Filing)$124.39M
Total Debt (Recent Filing)$29.83M
Price to Earnings (P/E)―
Beta1.24
Next Earnings
Mar 26, 2026EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.14
Shares Outstanding203,467,850
10 Day Avg. Volume1,600,678
30 Day Avg. Volume1,439,908
Financial Highlights & Ratios
PEG Ratio-0.14
Price to Book (P/B)3.55
Price to Sales (P/S)0.00
P/FCF Ratio-6.83
Enterprise Value/Market Cap1.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-798.40
Enterprise Value/Ebitda-9.24
Forecast
1Y Price Target
$10.25Price Target Upside94.50% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.44
Revenue Forecast (FY)$14.01M
Bulls Say, Bears Say
Bulls Say
Clinical Evidence And KOL SupportPublished Phase 3 results showing durable benefits and favorable safety, combined with key opinion leader endorsements of easy administration, support strong physician willingness to prescribe MOLBREEVI across disease severities.
Patient Identification And DiagnosticsBroader availability of a simple finger‑prick antibody test is revealing many previously missed aPAP cases, expanding the potential treated population and creating greater demand for an approved therapy.
Regulatory ProgressBLA resubmission with a new drug substance manufacturer and a requested Priority Review strengthens the regulatory pathway for MOLBREEVI and raises the likelihood of a faster approval decision.
Bears Say
Cash Runway And Financing RiskHigh cash burn and an unclear cash runway could require additional financing, creating dilution risk and potential disruption to commercialization plans.
Reimbursement And Patient AccessFrequent insurance denials and high out‑of‑pocket costs for off‑label treatments highlight potential payor resistance that could limit patient access and uptake of an approved product.
Treatment Pathway Adoption BarrierEstablished clinical practice of using whole lung lavage as the initial therapy for severe cases may slow first‑line adoption of MOLBREEVI and restrain early market penetration.
Savara News
SVRA FAQ
What was Savara’s price range in the past 12 months?
Savara lowest stock price was $1.89 and its highest was $7.00 in the past 12 months.
What is Savara’s market cap?
Savara’s market cap is $1.07B.
When is Savara’s upcoming earnings report date?
Savara’s upcoming earnings report date is Mar 26, 2026 which is in 17 days.
How were Savara’s earnings last quarter?
Savara released its earnings results on Nov 12, 2025. The company reported -$0.14 earnings per share for the quarter, missing the consensus estimate of -$0.132 by -$0.008.
Is Savara overvalued?
According to Wall Street analysts Savara’s price is currently Undervalued.
Does Savara pay dividends?
Savara does not currently pay dividends.
What is Savara’s EPS estimate?
Savara’s EPS estimate is -0.12.
How many shares outstanding does Savara have?
Savara has 203,467,850 shares outstanding.
What happened to Savara’s price movement after its last earnings report?
Savara reported an EPS of -$0.14 in its last earnings report, missing expectations of -$0.132. Following the earnings report the stock price went up 3.398%.
Which hedge fund is a major shareholder of Savara?
Currently, no hedge funds are holding shares in SVRA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Savara Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$10.25 (94.50% Upside)
$10.25 (94.50% Upside)
Blogger Sentiment
Bullish
SVRA Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 9.5M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $121.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 2.4%
Last 30 Days ▼ 2.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
102.69%
12-Months-Change
Fundamentals
Return on Equity
-86.60%
Trailing 12-Months
Asset Growth
-40.99%
Trailing 12-Months
Company Description
Savara
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.
SVRA Stock 12 Month Forecast
Average Price Target
$10.25
▲(94.50% Upside)
Technical Analysis
Ownership Overview
12.06% Insiders
6.57% Mutual Funds
18.01% Other Institutional Investors
53.82% Public Companies and
Individual Investors